Merck Reportedly Nearing $1.3B Acquisition Of EyeBio To Expand Eye-Care Market Presence
Portfolio Pulse from Benzinga Neuro
Merck & Co., Inc. (NYSE:MRK) is reportedly nearing a $1.3 billion acquisition of EyeBio to expand its presence in the eye-care market. The acquisition includes an upfront payment of $1.3 billion and potential additional payments of up to $1.7 billion based on milestones. EyeBio's lead drug, Restoret, is in development for treating age-related macular degeneration (AMD) and diabetic macular edema. This move is part of Merck's strategy to diversify its portfolio beyond its top-selling drug, Keytruda, which will lose patent protection in 2028.
May 29, 2024 | 8:36 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Merck's acquisition of EyeBio for $1.3 billion aims to expand its presence in the eye-care market and diversify its portfolio beyond Keytruda. This strategic move could provide new revenue streams as Keytruda's patent protection ends in 2028.
The acquisition of EyeBio is a strategic move for Merck to diversify its portfolio and reduce dependence on Keytruda, which will lose patent protection in 2028. The eye-care market is growing, and EyeBio's lead drug, Restoret, has potential in treating AMD and diabetic macular edema. This could positively impact Merck's revenue streams in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100